Loading ...
histology , age vs. comorbidity , and performance status ( PS ) ( 33(passive) might be influenced bycytotoxic combination chemotherapy
the identification and quantification of determinants of resistance or sensitivity to each single drug ... an important toolto designindividual combination chemotherapy
adverse side - effectsresultingfrom combination chemotherapy
the concomitantsetup with combination chemotherapy
Different treatmentsettingCombination with chemotherapy
histology , age , comorbidity , and performance status(passive) might be influenced bycytotoxic combination chemotherapy
on the basis of mechanism of action of the drugs , tumor cell specificity , balance between effectiveness and toxicity , and synergy between drugs(passive) have been designedCombination chemotherapy regimens
to assist in this position for appropriate choice(passive) are designedThe combination chemotherapy regimens
a routine procedureto designcombination chemotherapy
Primary hyperparathyroidismleadsto combination chemotherapy
pharmacokinetic / enhanced pharmacodynamic modelsto designmultidrug combination chemotherapy
in improved response rates but was associated with increased toxicity and no improvement in overall survivalresultedin improved response rates but was associated with increased toxicity and no improvement in overall survival
to a full recoveryledto a full recovery
to improved response rates and overall clinical benet compared with single agentsleadsto improved response rates and overall clinical benet compared with single agents
of nitrogen mustard , vincristine , prednisone and procarbazine ( MOPP regimen ) in 1964 by DeVitacomposedof nitrogen mustard , vincristine , prednisone and procarbazine ( MOPP regimen ) in 1964 by DeVita
in an objective response in about 40 of patients previously unexposed to chemotherapyresultsin an objective response in about 40 of patients previously unexposed to chemotherapy
of epirubicin , cyclophosphamide and carboplatin for 6 monthscomposedof epirubicin , cyclophosphamide and carboplatin for 6 months
side effects(passive) caused byside effects
grade IV leukopenia and neutropenia(passive) caused bygrade IV leukopenia and neutropenia
in higher response rates than treatment with single agentsresultsin higher response rates than treatment with single agents
in 10-year disease - free survival ( DFS ) and overall survival ( OS ) rates of 57 % to 81 % and 57 % to 89 % , respectively.[6,7,8,9 ] For patients who experience a relapse after initial combination chemotherapyresultsin 10-year disease - free survival ( DFS ) and overall survival ( OS ) rates of 57 % to 81 % and 57 % to 89 % , respectively.[6,7,8,9 ] For patients who experience a relapse after initial combination chemotherapy
in somewhat higher response rates of 10–40%(7has resultedin somewhat higher response rates of 10–40%(7
to Comparable Overall Survival and Relapse - Free Survival RatesLeadsto Comparable Overall Survival and Relapse - Free Survival Rates
in 10-year disease - free survival ( DFS ) and overall survival ( OS ) rates of 57 % to 81 % and 57 % to 89 % , respectively.[1,2,3,4 ] For patients who experience a re Laetrile Effectiveness Cancer & Oncology 6/17/2019 7:46:00 AMresultsin 10-year disease - free survival ( DFS ) and overall survival ( OS ) rates of 57 % to 81 % and 57 % to 89 % , respectively.[1,2,3,4 ] For patients who experience a re Laetrile Effectiveness Cancer & Oncology 6/17/2019 7:46:00 AM
to complete remission for certain types of cancercould leadto complete remission for certain types of cancer
in a complete remission rate of 75 % or greater in dogsresultsin a complete remission rate of 75 % or greater in dogs
selective tumor lysis and immunotherapy and immune modulator ( IMiD ) combinations to produce innate and adaptive immune responsesto triggerselective tumor lysis and immunotherapy and immune modulator ( IMiD ) combinations to produce innate and adaptive immune responses
selective tumor lysis and immuno - therapy and immune modulator ( IMiD ) combinations to produce innate and adaptie immune responsesto triggerselective tumor lysis and immuno - therapy and immune modulator ( IMiD ) combinations to produce innate and adaptie immune responses
selective tumor lysis and immuno - therapy and immune modulator ( IMiD ) combinations to produce innate and adaptive immune responsesto triggerselective tumor lysis and immuno - therapy and immune modulator ( IMiD ) combinations to produce innate and adaptive immune responses
to 2-year survival rate of 62 % ... but hastened to point out that different classes of non - small cell lung cancer ( NSCLC ) might respond differently to ICIledto 2-year survival rate of 62 % ... but hastened to point out that different classes of non - small cell lung cancer ( NSCLC ) might respond differently to ICI
to higher response rates and progression - free survival compared with monotherapy for patients with advanced rectal cancerhas ledto higher response rates and progression - free survival compared with monotherapy for patients with advanced rectal cancer
to outcomes that are more than simply additive and that high - atomic number nanostructured particles can be customised for radiotherapy to increase radiation - induced effects for the very radioresistant 9L cancer cellscan leadto outcomes that are more than simply additive and that high - atomic number nanostructured particles can be customised for radiotherapy to increase radiation - induced effects for the very radioresistant 9L cancer cells
considerably higher toxicity than single - agent chemotherapycausesconsiderably higher toxicity than single - agent chemotherapy
in normalization of the serum calcium level and improvementresultedin normalization of the serum calcium level and improvement
of bleomycin , etoposide and cisplatincomposedof bleomycin , etoposide and cisplatin
acute and long - term toxicitycausesacute and long - term toxicity
to a radiological regression of the lymphadenopathy andledto a radiological regression of the lymphadenopathy and
the hematotoxicities(passive) caused bythe hematotoxicities
to significantly better treatment outcomes compared to monotherapyledto significantly better treatment outcomes compared to monotherapy
in a response rate of 30%–54 % and a median OS of 8–13 monthscan resultin a response rate of 30%–54 % and a median OS of 8–13 months
to cure of a majority of children with this diseaseledto cure of a majority of children with this disease
of cyclophosphamide , vincristine , doxorubicin and prednisolone ( CHOPcomposedof cyclophosphamide , vincristine , doxorubicin and prednisolone ( CHOP
of drugs like tamoxifen , cisplatin , and dacarbazinecomposedof drugs like tamoxifen , cisplatin , and dacarbazine
reductions above 90 percentcausedreductions above 90 percent
greater tumour cell killcan causegreater tumour cell kill
75 % remission and of those 50 % curedcauses75 % remission and of those 50 % cured
to measurable improvements in cancer treatment outcomeshas ledto measurable improvements in cancer treatment outcomes
long - term peripheral neuropathyinfluencedlong - term peripheral neuropathy
in significant prolongation of OS and time to progression and superior tumor response but more toxicity in women with metastatic breast cancer ... Carrick et al .resultedin significant prolongation of OS and time to progression and superior tumor response but more toxicity in women with metastatic breast cancer ... Carrick et al .
of folinic acidis composedof folinic acid
to a high rate of cure ( > 80 %ledto a high rate of cure ( > 80 %